Search results for "Rejection"

showing 10 items of 169 documents

Exact simulation of first exit times for one-dimensional diffusion processes

2019

International audience; The simulation of exit times for diffusion processes is a challenging task since it concerns many applications in different fields like mathematical finance, neuroscience, reliability horizontal ellipsis The usual procedure is to use discretization schemes which unfortunately introduce some error in the target distribution. Our aim is to present a new algorithm which simulates exactly the exit time for one-dimensional diffusions. This acceptance-rejection algorithm requires to simulate exactly the exit time of the Brownian motion on one side and the Brownian position at a given time, constrained not to have exit before, on the other side. Crucial tools in this study …

Girsanov theoremand phrases: Exit timeDiscretizationsecondary: 65N75Exit time Brownian motion diffusion processes Girsanov’s transformation rejection sampling exact simulation randomized algorithm conditioned Brownian motion.MSC 65C05 65N75 60G40Exit time01 natural sciencesGirsanov’s transformationrandomized algorithm010104 statistics & probabilityrejection samplingGirsanov's transformationexact simulationFOS: MathematicsApplied mathematicsMathematics - Numerical Analysis0101 mathematicsConvergent seriesBrownian motion60G40MathematicsNumerical AnalysisApplied MathematicsMathematical financeRejection samplingProbability (math.PR)diffusion processesNumerical Analysis (math.NA)conditioned Brownian motionRandomized algorithm010101 applied mathematics[MATH.MATH-PR]Mathematics [math]/Probability [math.PR]Computational MathematicsModeling and Simulationconditioned Brownian motion 2010 AMS subject classifications: primary 65C05Brownian motionRandom variableMathematics - ProbabilityAnalysis[MATH.MATH-NA]Mathematics [math]/Numerical Analysis [math.NA]
researchProduct

Anti-HLA immunization of patients qualified for lung transplantation – Single center study

2021

For lung transplantation, the presence of donor-specific anti-HLA antibodies (DSA) is an important factor of antibody-mediated rejection (AMR) in its hyperacute, acute or chronic form during long-term follow up. The aim of the study was to assess the allosensitization of Polish patients qualified for a lung transplantation in our center. A retrospective study of 161 potential lung allograft recipients, also of 31 patients transplanted in the Uni-versity Hospital of Gdansk, between June 2018 and December 2020 were performed. 121 potential recipients were thoroughly tested for immunization status before eventual lung transplantation. SAB-testing, PRA-CDC and vPRA assessment, and HLA typing we…

Graft RejectionAnti-HLA sensitizationTransplantationHistocompatibility TestingImmunologyKidney TransplantationTransplant immunologyHLA AntigensIsoantibodiesHumansImmunology and AllergyImmunizationLung TransplantationRetrospective StudiesTransplant Immunology
researchProduct

Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial

2012

    In a prospective, multicenter, open-label study, de novo liver transplant patients were randomized at day 30±5 to (i) everolimus initiation with tacrolimus elimination (TAC Elimination) (ii) everolimus initiation with reduced-exposure tacrolimus (EVR+Reduced TAC) or (iii) standard-exposure tacrolimus (TAC Control). Randomization to TAC Elimination was terminated prematurely due to a higher rate of treated biopsy-proven acute rejection (tBPAR). EVR+Reduced TAC was noninferior to TAC Control for the primary efficacy endpoint (tBPAR, graft loss or death at 12 months posttransplantation): 6.7% versus 9.7% (-3.0%; 95% CI -8.7, 2.6%; p<0.001 for noninferiority [12% margin]). tBPAR occurred in…

Graft RejectionCHRONIC KIDNEY-DISEASEMaleTime Factorsmedicine.medical_treatmentMedizinKaplan-Meier EstimateLiver transplantationKidneyKidney Function TestsGLOMERULAR-FILTRATION-RATEImmunosuppressive AgentHEPATOCELLULAR-CARCINOMASIROLIMUS-BASED IMMUNOSUPPRESSIONImmunology and AllergySirolimuPharmacology (medical)Prospective StudiestacrolimusMYCOPHENOLATE-MOFETILCOMPLICATIONSCross-Over Studiesliver transplantationwithdrawalGraft SurvivalCross-Over StudieMiddle AgedTreatment Outcomesurgical procedures operativeSurvival AnalysireducedLife Sciences & BiomedicineImmunosuppressive AgentsHumanGlomerular Filtration Ratemedicine.drugAdultmedicine.medical_specialtyRandomizationTime FactorAdolescentEfficacyUrologyRenal functionchemical and pharmacologic phenomenaCALCINEURIN INHIBITORRisk AssessmentDrug Administration ScheduleFollow-Up StudieYoung Adultstomatognathic systemTransplantation ImmunologyDOSE TACROLIMUSConfidence IntervalsmedicineHumansMETAANALYSISAgedSirolimusTransplantationKidney Function TestScience & TechnologyEverolimusDose-Response Relationship Drugbusiness.industryeverolimutacrolimuOriginal ArticleseverolimusSurvival AnalysisCrossover studyTacrolimusSurgeryTransplantationProspective StudieCONVERSIONstomatognathic diseasesSirolimusSurgerybusinessConfidence IntervalLiver FailureFollow-Up StudiesAmerican Journal of Transplantation
researchProduct

Wharton’s Jelly Mesenchymal Stem Cells as Candidates for Beta Cells Regeneration: Extending the Differentiative and Immunomodulatory Benefits of Adul…

2010

Mesenchymal stem cells (MSC) are uniquely capable of crossing germinative layers borders (i.e. are able to differentiate towards ectoderm-, mesoderm- and endoderm-derived cytotypes) and are viewed as promising cells for regenerative medicine approaches in several diseases. Type I diabetes therapy should potentially benefit from such differentiated cells: the search for alternatives to organ/islet transplantation strategies via stem cells differentiation is an ongoing task, significant goals having been achieved in most experimental settings (e.g. insulin production and euglycaemia restoration), though caution is still needed to ensure safe and durable effects in vivo. MSC are obtainable in …

Graft RejectionCancer ResearchCellular differentiationCell Culture TechniquesClinical uses of mesenchymal stem cellsBiologyMesenchymal Stem Cell TransplantationRegenerative medicineUmbilical CordImmunomodulationMesenchymal stem cells Umbilical cord Wharton’s jelly Type 1 diabetes Beta cells Differentiation markers Pancreas development Inflammation Immune modulation HypoimmunogenicityInsulin-Secreting CellsWharton's jellyAnimalsHumansRegenerationEmbryonic Stem CellsSettore BIO/16 - Anatomia UmanaRegeneration (biology)Mesenchymal stem cellCell DifferentiationMesenchymal Stem CellsCell BiologyAntigens DifferentiationTransplantationAdult Stem CellsDiabetes Mellitus Type 1Adipose TissueImmunologyCancer researchCord Blood Stem Cell TransplantationStem cellStem Cell Reviews and Reports
researchProduct

The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells.

2000

The low immunogenic B16 melanoma cell line was transfected with a mammalian expression vector containing the complementary DNA for a sIL-6R/IL-6 fusion protein, termed Hyper-IL-6 (H-IL-6), which was shown to have biological activities at 100-1000-fold lower concentrations than IL-6 in combination with sIL-6R. The secreted p84 glycoprotein was detected in the supernatant of transfected cells and was fully active on BAF3/gp130 cells, which respond to IL-6/sIL-6R but not to IL-6 alone. Administration of recombinant H-IL-6 to C57BL/6 mice resulted in a prolonged acute phase protein gene expression indicating long systemic persistence of the fusion protein. Transfected B16 cells (B16/H-IL6 cells…

Graft RejectionCancer ResearchTumor suppressor geneRatónmedicine.medical_treatmentRecombinant Fusion ProteinsMelanoma ExperimentalMice TransgenicTransfectionchemistry.chemical_compoundMiceGene expressionGeneticsmedicineAnimalsDrug InteractionsInterleukin 6neoplasmsMolecular BiologybiologyInterleukin-6MelanomaGranulocyte-Macrophage Colony-Stimulating FactorReceptors Interleukinmedicine.diseaseReceptors Interleukin-6Growth Inhibitorsrespiratory tract diseasesCytokinechemistryCell cultureReceptors Granulocyte-Macrophage Colony-Stimulating FactorImmunologybiology.proteinCancer researchGrowth inhibitionImmunosuppressive AgentsOncogene
researchProduct

Polymorphism in the immunoglobulin-like domains of the receptor tyrosine kinase from the sponge Geodia cydonium.

1996

Sponges [Porifera] are the phylogenetically oldest phylum of the Metazoa. They are provided with both cellular and humoral allorecognition systems. The underlying molecules are not yet known. To study allorecognition in sponges we first determined the frequency of graft rejection in a natural population of the marine sponge Geodia cydonium. We then determined, for the first time at the molecular level, the degree of sequence polymorphism in segments of one molecule which may be related to sponge allorecognition and host defense: the Ig-like domains from the receptor tyrosine kinase [RTK]. Thirty six pairs of auto- and allografts were assayed, either by parabiotic attachment or insertion of …

Graft RejectionDNA ComplementaryGeodia cydoniumMolecular Sequence DataImmunoglobulinsPolymerase Chain ReactionReceptor tyrosine kinaseMolecular levelSequence Homology Nucleic AcidAnimalsGeodiaAmino Acid SequenceAllorecognitionGene LibraryPolymorphism GeneticGraft rejectionbiologyBase SequenceSequence Homology Amino AcidReceptor Protein-Tyrosine KinasesGeneral MedicineAnatomySequence Analysis DNAbiology.organism_classificationCell biologyPoriferaSpongesurgical procedures operativebiology.proteinAntibodyCell adhesion and communication
researchProduct

Suppression of allograft rejection in the sponge Suberites domuncula by FK506 and expression of genes encoding FK506-binding proteins in allografts.

2001

SUMMARY Porifera (sponges) are, evolutionarily, the oldest metazoan phylum. Recent molecular data suggest that these animals possess molecules similar to and homologous with those of the innate and adaptive immune systems of higher Metazoa. Applying the biological system of parabiosis and the technique of differential display of mRNA, two cDNAs encoding putative FK506-binding proteins were isolated. FK506 is successfully used in clinics as a drug to prevent allograft rejection and is toxic to Suberites domuncula cells in vitro at doses above 100ng ml−1. Autograft fusion of transplants from S. domuncula was not affected by FK506. Allograft non-fusion was not affected by FK506 at toxic doses;…

Graft RejectionDNA ComplementaryPhysiologyParabiosisMolecular Sequence DataGene ExpressionSequence HomologyAquatic SciencePolymerase Chain ReactionTacrolimusTacrolimus Binding ProteinsImmune systempolycyclic compoundsHomologous chromosomeAnimalsTransplantation HomologousAmino Acid SequenceCloning MolecularMolecular BiologyGeneEcology Evolution Behavior and SystematicsGene LibraryMessenger RNADifferential displaybiologyAnatomybiology.organism_classificationIn vitroCell biologyPoriferaSuberites domunculaInsect ScienceAnimal Science and ZoologyThe Journal of experimental biology
researchProduct

Clinical Predictors of Immunotolerance in Heart Transplantation

2010

Abstract Background and Aim The drugs routinely administered to prevent rejection often cause lethal side effects. Tolerant patients, therefore, should be identified to minimize these problems. The aim of this analysis was to identify clinical variables that may be associated with tolerance. Methods We recruited 522 heart transplants (HT), excluding combined procedures, retransplantations, pediatric recipients, and subjects who died in the first year to obtain a cohort of 375 patients. Two groups were distinguished by the presence of echocardiographic, clinical, or pathological evidence of rejection in the first year (15 echocardiograms and 10 protocol biopsies per patient); 99 tolerant pat…

Graft RejectionHeart transplantationTransplantationmedicine.medical_specialtyUnivariate analysisMultivariate analysisbusiness.industrymedicine.medical_treatmentSurgeryMajor Histocompatibility ComplexTransplantationElectrocardiographyText miningInternal medicineCohortImmune TolerancemedicineHeart TransplantationHumansSurgerybusinessPathologicalSurvival analysisTransplantation Proceedings
researchProduct

Protective role of the complement regulatory protein human CD-55 in cardiac xenograft: a descriptive study and a revision of the literature.

2002

The limited and inadequate availability of organs from human donors has resulted in the utilisation of xenografts as an alternative tool. Nevertheless, hyperacute rejection (HAR) following xenograft determines the loss of the transplanted organ. The “primum movens” is the activation of the complement pathway mediated by the binding of natural xenogenic antibodies to the endothelium of the graft, followed by the lysis of the endothelial cells with subsequent oedema, thrombosis and necrosis of the transplanted organ. In this work we describe morphological and biomolecular observations of isolated human-decay accelerating factor (h-DAF, CD55) transgenic pig hearts, after perfusion for four hou…

Graft RejectionHistologyCD55 AntigensSwineEndothelial cells2734Blotting WesternTransplantation HeterologousComplementCell BiologyOrgan SizeImmunohistochemistryMicroscopy ElectronEndothelial cellMembrane glycoproteinCoronary CirculationGenetic engineering:6 - Ciencias aplicadas::61 - Medicina::611 - Anatomía [CDU]AnimalsHeart TransplantationHumansXenotransplantationAnatomyComplement; Endothelial cells; Genetic engineering; Membrane glycoproteins; Xenotransplantation; Anatomy; 2734; Histology; Cell Biology
researchProduct

Differential diagnosis of cytomegalovirus infection and acute rejection by serum CC-Chemokine measurement after orthotopic liver transplantation

2003

Graft RejectionHuman cytomegalovirusPathologymedicine.medical_specialtyOpportunistic infectionCC chemokinemedicine.disease_causeHerpesviridaeVirusDiagnosis DifferentialBetaherpesvirinaemedicineHumansTransplantationbiologybusiness.industrymedicine.diseasebiology.organism_classificationLiver TransplantationChemokines CCAcute DiseaseCytomegalovirus InfectionsSurgeryViral diseaseDifferential diagnosisbusinessBiomarkersTransplantation Proceedings
researchProduct